All News
Filter News
Found 420 articles
-
Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
5/25/2023
Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell-based therapies, announced the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.
-
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
5/25/2023
Affimed N.V. announced the publication of two abstracts with its innate cell engager AFM24 in advance of the American Society of Clinical Oncology Annual Meeting, taking place on June 2 - 6, 2023 in Chicago, IL.
-
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
5/23/2023
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results and provided an update on clinical and corporate progress for the first quarter of 2023.
-
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
5/23/2023
Affimed N.V. announced that the U.S. Food and Drug Administration has cleared its IND application for the combination of AFM13, its first-in-class tetravalent bispecific innate cell engager and AB-101, Artiva Biotherapeutics Inc.’s clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived natural killer cells to initiate the clinical trial, AFM13-203.
-
Affimed Announces Annual General Meeting of Shareholders - May 22, 2023
5/22/2023
Affimed N.V. announced that its 2023 Annual General Meeting of Shareholders will be held on June 21, 2023 at 14:00 CET at the NH Collection Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands.
-
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
5/16/2023
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023.
-
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
5/11/2023
Affimed N.V. announced that two abstracts have been accepted to EHA2023, the annual meeting of the European Hematology Association taking place in Frankfurt, Germany on June 8-11, 2023.
-
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
4/26/2023
Affimed N.V. announced that two abstracts with its innate cell engager AFM24 have been accepted for the American Society of Clinical Oncology Annual Meeting, taking place June 2 - 6, 2023 in Chicago, IL.
-
Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
4/26/2023
Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago.
-
Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.
-
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
4/17/2023
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster developed in collaboration with Prof. Björn Önfelt from the KTH Royal Institute of Technology and Karolinska Institute in Stockholm.
-
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the AACR Annual Meeting 2023
4/16/2023
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, provided the final results from its phase 2 REDIRECT study investigating its innate cell engager AFM13 monotherapy in patients with heavily pretreated advanced-stage r/r PTCL.
-
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - April 06, 2023
4/6/2023
Affimed N.V. announced that it has received a written notice, dated April 4, 2023, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, for the last thirty consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550.
-
GC Cell and New Management Embarking on a New Chapter
4/3/2023
GC Cell, a Korean biotech company, announced on Mar. 28th that it had held the 12th General Shareholders' Meeting at GC Biopharma R&D Center in Yongin, Gyeonggi-do of South Korea and resolved some major agenda items, including the appointment of inside directors.
-
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
3/29/2023
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the first patient was dosed in a phase 1 multicenter, open label, first-in-human dose escalation study of the innate cell engager AFM28 monotherapy in patients with CD123-positive relapsed/refractory acute myeloid leukemia.
-
Affimed Reports 2022 Financial Results and Operational Progress
3/23/2023
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.
-
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
3/16/2023
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release full year 2022 results and corporate update on Thursday, March 23, 2023.
-
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the AACR
3/14/2023
Affimed N.V. announced that two abstracts with clinical and preclinical data on AFM13, its anti-CD30 targeting innate cell engager, have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research, taking place April 14-19, 2022 in Orlando, Florida.
-
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
3/9/2023
AbCheck s.r.o. announced that it has successfully completed the technology development activities specified under the terms of its research grant entitled “Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect”.
-
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
2/22/2023
Affimed N.V. announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.